6 results on '"Qiao, Zhu"'
Search Results
2. Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia
- Author
-
Qiu-Sha Huang, Jing-Zhi Wang, Ya-Zhen Qin, Qiao-Zhu Zeng, Qian Jiang, Hao Jiang, Jin Lu, Hui-Xin Liu, Yi Liu, Jing-Bo Wang, Li Su, Hong-Yu Zhang, Zhen-Ling Li, Su-Jun Gao, Bo Huang, Yu-Ying Liu, Yan-Rong Liu, Lan-Ping Xu, Xiao-Jun Huang, and Xiao-Hui Zhang
- Subjects
Specialties of internal medicine ,RC581-951 - Abstract
Abstract: Thrombocytopenia is associated with life-threatening bleeding and is common in myelodysplastic syndromes (MDS). Robust molecular prognostic biomarkers need to be developed to improve clinical decision making for patients with MDS with thrombocytopenia. Wilms tumor 1 (WT1) and preferentially expressed antigen in melanoma (PRAME) are promising immunogenic antigen candidates for immunotherapy, and their clinical effects on patients with MDS with thrombocytopenia are still not well understood. We performed a multicenter observational study of adult patients with MDS with thrombocytopenia from 7 different tertiary medical centers in China. We examined bone marrow samples collected at diagnosis for WT1 and PRAME transcript levels and then analyzed their prognostic effect for patients with MDS with thrombocytopenia. In total, we enrolled 1110 patients diagnosed with MDS with thrombocytopenia. Overexpression of WT1 and PRAME was associated with elevated blast percentage, worse cytogenetics, and higher Revised International Prognostic Scoring System (IPSS-R) risk. Further, both WT1 and PRAME overexpression were independent poor prognostic factors for acute myeloid leukemia evolution, overall survival, and progression-free survival. Together, the 2 genes overexpression identified a population of patients with MDS with substantially worse survival. On the basis of WT1 and PRAME transcript levels, patients with MDS with IPSS-R low risk were classified into 2 significantly divergent prognostic risk groups: a low-favorable group and a low-adverse group. The low-adverse group had survival similar to that of patients in the intermediate-risk group. Our study demonstrates that the evaluation of WT1/PRAME transcript analysis may improve the prognostication precision and better risk-stratify the patients.
- Published
- 2019
- Full Text
- View/download PDF
3. Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia
- Author
-
Huang, Qiu-Sha, Wang, Jing-Zhi, Qin, Ya-Zhen, Zeng, Qiao-Zhu, Jiang, Qian, Jiang, Hao, Lu, Jin, Liu, Hui-Xin, Liu, Yi, Wang, Jing-Bo, Su, Li, Zhang, Hong-Yu, Li, Zhen-Ling, Gao, Su-Jun, Huang, Bo, Liu, Yu-Ying, Liu, Yan-Rong, Xu, Lan-Ping, Huang, Xiao-Jun, and Zhang, Xiao-Hui
- Published
- 2019
- Full Text
- View/download PDF
4. A risk score for predicting hospitalization for community-acquired pneumonia in ITP using nationally representative data
- Author
-
Hao Jiang, Qiu-Sha Huang, Hui Liu, Ze-Ping Zhou, Jun Peng, Lin-Hua Yang, Xiao-Su Zhao, Jia Feng, Ming Hou, Xu-Liang Shen, Xiang-Yu Zhao, Ye-Jun Wu, Wen-Sheng Wang, Qianfei Wang, Ying-Jun Chang, Xing-Lin Wang, Xiao-Hui Zhang, Yue-Ying Li, Qiao-Zhu Zeng, Ru Feng, Hai-Xia Fu, Lan-Ping Xu, Yun He, Peng Zhao, Hongyu Zhang, Liang-Ming Ma, Qian Jiang, Yi Liu, Hui-Xin Liu, and Jin Lu
- Subjects
Adult ,China ,medicine.medical_specialty ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Community-acquired pneumonia ,Risk Factors ,immune system diseases ,Internal medicine ,medicine ,Humans ,Retrospective Studies ,Purpura, Thrombocytopenic, Idiopathic ,Framingham Risk Score ,business.industry ,Incidence (epidemiology) ,Area under the curve ,Retrospective cohort study ,Pneumonia ,Hematology ,medicine.disease ,Confidence interval ,Hospitalization ,Decision curve analysis ,Erratum ,business ,030215 immunology - Abstract
Infection is one of the primary causes of death from immune thrombocytopenia (ITP), and the lungs are the most common site of infection. We identified the factors associated with hospitalization for community-acquired pneumonia (CAP) in nonsplenectomized adults with ITP and established the ACPA prediction model to predict the incidence of hospitalization for CAP. This was a retrospective study of nonsplenectomized adult patients with ITP from 10 large medical centers in China. The derivation cohort included 145 ITP inpatients with CAP and 1360 inpatients without CAP from 5 medical centers, and the validation cohort included the remaining 63 ITP inpatients with CAP and 526 inpatients without CAP from the other 5 centers. The 4-item ACPA model, which included age, Charlson Comorbidity Index score, initial platelet count, and initial absolute lymphocyte count, was established by multivariable analysis of the derivation cohort. Internal and external validation were conducted to assess the performance of the model. The ACPA model had an area under the curve of 0.853 (95% confidence interval [CI], 0.818-0.889) in the derivation cohort and 0.862 (95% CI, 0.807-0.916) in the validation cohort, which indicated the good discrimination power of the model. Calibration plots showed high agreement between the estimated and observed probabilities. Decision curve analysis indicated that ITP patients could benefit from the clinical application of the ACPA model. To summarize, the ACPA model was developed and validated to predict the occurrence of hospitalization for CAP, which might help identify ITP patients with a high risk of hospitalization for CAP.
- Published
- 2020
5. Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia
- Author
-
Bo Huang, Xiao-Jun Huang, Hui-Xin Liu, Yan-Rong Liu, Hongyu Zhang, Xiao-Hui Zhang, Jing-Bo Wang, Ya-Zhen Qin, Hao Jiang, Qian Jiang, Yi Liu, Li Su, Su-Jun Gao, Jin Lu, Jing-Zhi Wang, Yuying Liu, Qiu-Sha Huang, Qiao-Zhu Zeng, Lan-Ping Xu, and Zhen-Ling Li
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,Population ,Gene Expression ,Antigens, Neoplasm ,hemic and lymphatic diseases ,Internal medicine ,Humans ,Medicine ,WT1 Proteins ,education ,Aged ,Retrospective Studies ,education.field_of_study ,PRAME ,Myeloid Neoplasia ,business.industry ,Melanoma ,Myelodysplastic syndromes ,Disease Management ,Myeloid leukemia ,Wilms' tumor ,Hematology ,Middle Aged ,Prognosis ,medicine.disease ,Combined Modality Therapy ,Survival Analysis ,Thrombocytopenia ,Cell Transformation, Neoplastic ,Treatment Outcome ,medicine.anatomical_structure ,International Prognostic Scoring System ,Myelodysplastic Syndromes ,Female ,Bone marrow ,business ,Algorithms ,Biomarkers - Abstract
Thrombocytopenia is associated with life-threatening bleeding and is common in myelodysplastic syndromes (MDS). Robust molecular prognostic biomarkers need to be developed to improve clinical decision making for patients with MDS with thrombocytopenia. Wilms tumor 1 (WT1) and preferentially expressed antigen in melanoma (PRAME) are promising immunogenic antigen candidates for immunotherapy, and their clinical effects on patients with MDS with thrombocytopenia are still not well understood. We performed a multicenter observational study of adult patients with MDS with thrombocytopenia from 7 different tertiary medical centers in China. We examined bone marrow samples collected at diagnosis for WT1 and PRAME transcript levels and then analyzed their prognostic effect for patients with MDS with thrombocytopenia. In total, we enrolled 1110 patients diagnosed with MDS with thrombocytopenia. Overexpression of WT1 and PRAME was associated with elevated blast percentage, worse cytogenetics, and higher Revised International Prognostic Scoring System (IPSS-R) risk. Further, both WT1 and PRAME overexpression were independent poor prognostic factors for acute myeloid leukemia evolution, overall survival, and progression-free survival. Together, the 2 genes overexpression identified a population of patients with MDS with substantially worse survival. On the basis of WT1 and PRAME transcript levels, patients with MDS with IPSS-R low risk were classified into 2 significantly divergent prognostic risk groups: a low-favorable group and a low-adverse group. The low-adverse group had survival similar to that of patients in the intermediate-risk group. Our study demonstrates that the evaluation of WT1/PRAME transcript analysis may improve the prognostication precision and better risk-stratify the patients.
- Published
- 2019
6. Overexpression of WT1and PRAMEpredicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia
- Author
-
Huang, Qiu-Sha, Wang, Jing-Zhi, Qin, Ya-Zhen, Zeng, Qiao-Zhu, Jiang, Qian, Jiang, Hao, Lu, Jin, Liu, Hui-Xin, Liu, Yi, Wang, Jing-Bo, Su, Li, Zhang, Hong-Yu, Li, Zhen-Ling, Gao, Su-Jun, Huang, Bo, Liu, Yu-Ying, Liu, Yan-Rong, Xu, Lan-Ping, Huang, Xiao-Jun, and Zhang, Xiao-Hui
- Abstract
Thrombocytopenia is associated with life-threatening bleeding and is common in myelodysplastic syndromes (MDS). Robust molecular prognostic biomarkers need to be developed to improve clinical decision making for patients with MDS with thrombocytopenia. Wilms tumor 1 (WT1) and preferentially expressed antigen in melanoma (PRAME) are promising immunogenic antigen candidates for immunotherapy, and their clinical effects on patients with MDS with thrombocytopenia are still not well understood. We performed a multicenter observational study of adult patients with MDS with thrombocytopenia from 7 different tertiary medical centers in China. We examined bone marrow samples collected at diagnosis for WT1and PRAMEtranscript levels and then analyzed their prognostic effect for patients with MDS with thrombocytopenia. In total, we enrolled 1110 patients diagnosed with MDS with thrombocytopenia. Overexpression of WT1and PRAMEwas associated with elevated blast percentage, worse cytogenetics, and higher Revised International Prognostic Scoring System (IPSS-R) risk. Further, both WT1and PRAMEoverexpression were independent poor prognostic factors for acute myeloid leukemia evolution, overall survival, and progression-free survival. Together, the 2 genes overexpression identified a population of patients with MDS with substantially worse survival. On the basis of WT1and PRAMEtranscript levels, patients with MDS with IPSS-R low risk were classified into 2 significantly divergent prognostic risk groups: a low-favorable group and a low-adverse group. The low-adverse group had survival similar to that of patients in the intermediate-risk group. Our study demonstrates that the evaluation of WT1/PRAMEtranscript analysis may improve the prognostication precision and better risk-stratify the patients.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.